Literature DB >> 26886833

Transfer of the Cystic Fibrosis Transmembrane Conductance Regulator to Human Cystic Fibrosis Cells Mediated by Extracellular Vesicles.

Cyrielle Vituret1,2, Kathy Gallay1, Marie-Pierre Confort1, Najate Ftaich1, Constantin I Matei3, Fabienne Archer1, Corinne Ronfort1, Jean-François Mornex1, Marc Chanson4, Attilio Di Pietro2, Pierre Boulanger1, Saw See Hong1,5.   

Abstract

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, resulting in a deficiency in chloride channel activity. In this study, extracellular vesicles (EVs), microvesicles, and exosomes were used as vehicles to deliver exogenous CFTR glycoprotein and its encoding mRNA (mRNA(GFP-CFTR)) to CF cells to correct the CFTR chloride channel function. We isolated microvesicles and exosomes from the culture medium of CFTR-positive Calu-3 cells, or from A549 cells transduced with an adenoviral vector overexpressing a GFP-tagged CFTR (GFP-CFTR). Both microvesicles and exosomes had the capacity to package and deliver the GFP-CFTR glycoprotein and mRNA(GFP-CFTR) to target cells in a dose-dependent manner. Homologous versus heterologous EV-to-cell transfer was studied, and it appeared that the cellular uptake of EVs was significantly more efficient in homologous transfer. The incubation of CF15 cells, a nasal epithelial cell line homozygous for the ΔF508 CFTR mutation, with microvesicles or exosomes loaded with GFP-CFTR resulted in the correction of the CFTR function in CF cells in a dose-dependent manner. A time-course analysis of EV-transduced CF cells suggested that CFTR transferred as mature glycoprotein was responsible for the CFTR-associated channel activity detected at early times posttransduction, whereas GFP-CFTR translated from exogenous mRNA(GFP-CFTR) was responsible for the CFTR function at later times. Collectively, this study showed the potential application of microvesicles and exosomes as vectors for CFTR transfer and functional correction of the genetic defect in human CF cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26886833     DOI: 10.1089/hum.2015.144

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  13 in total

1.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

2.  Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.

Authors:  Chiara De Santi; Elena Fernández Fernández; Rachel Gaul; Sebastian Vencken; Arlene Glasgow; Irene K Oglesby; Killian Hurley; Finn Hawkins; Nilay Mitash; Fangping Mu; Rana Raoof; David C Henshall; Meritxell B Cutrona; Jeremy C Simpson; Brian J Harvey; Barry Linnane; Paul McNally; Sally Ann Cryan; Ronan MacLoughlin; Agnieszka Swiatecka-Urban; Catherine M Greene
Journal:  Mol Ther       Date:  2020-02-06       Impact factor: 11.454

3.  A Systematic Evaluation of Factors Affecting Extracellular Vesicle Uptake by Breast Cancer Cells.

Authors:  Devin M Stranford; Michelle E Hung; Emma S Gargus; Ramille N Shah; Joshua N Leonard
Journal:  Tissue Eng Part A       Date:  2017-07-20       Impact factor: 3.845

Review 4.  Advances in therapeutic applications of extracellular vesicles.

Authors:  Oscar P B Wiklander; Meadhbh Á Brennan; Jan Lötvall; Xandra O Breakefield; Samir El Andaloussi
Journal:  Sci Transl Med       Date:  2019-05-15       Impact factor: 17.956

5.  Endothelial Extracellular Vesicles in Pulmonary Function and Disease.

Authors:  Eleftheria Letsiou; Natalie Bauer
Journal:  Curr Top Membr       Date:  2018-10-08       Impact factor: 3.049

Review 6.  Extracellular Vesicles as Central Mediators of COPD Pathophysiology.

Authors:  Derek W Russell; Kristopher R Genschmer; J Edwin Blalock
Journal:  Annu Rev Physiol       Date:  2021-11-01       Impact factor: 19.318

Review 7.  Exosomes and Exosomal miRNA in Respiratory Diseases.

Authors:  Shamila D Alipoor; Esmaeil Mortaz; Johan Garssen; Masoud Movassaghi; Mehdi Mirsaeidi; Ian M Adcock
Journal:  Mediators Inflamm       Date:  2016-09-25       Impact factor: 4.711

8.  Evaluation of chemical chaperones based on the monitoring of Bip promoter activity and visualization of extracellular vesicles by real-time bioluminescence imaging.

Authors:  Tomohisa Horibe; Nanako Okushima; Aya Torisawa; Ryutaro Akiyoshi; Yoko Hatta-Ohashi; Hirobumi Suzuki; Koji Kawakami
Journal:  Luminescence       Date:  2017-09-20       Impact factor: 2.464

9.  Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator.

Authors:  Olga Villamizar; Shafagh A Waters; Tristan Scott; Sheena Saayman; Nicole Grepo; Ryan Urak; Alicia Davis; Adam Jaffe; Kevin V Morris
Journal:  Mol Ther       Date:  2019-07-15       Impact factor: 11.454

10.  Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis.

Authors:  Zivile Useckaite; Mark P Ward; Anne Trappe; Rebecca Reilly; Jenny Lennon; Holly Davage; David Matallanas; Hilary Cassidy; Eugene T Dillon; Kiva Brennan; Sarah L Doyle; Suzanne Carter; Seamas Donnelly; Barry Linnane; Edward F McKone; Paul McNally; Judith A Coppinger
Journal:  Thorax       Date:  2020-04-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.